These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34897593)

  • 1. Treatment of Psoriasis Vulgaris with Medicated Thread Moxibustion of Zhuang Medicine: A Multicenter Randomized, Parallel Controlled Trial.
    Pang YZ; Tang J; Zhang QH; Liang FZ; Fang G; Zhao C; Shang HC; Wang LY; Wang YP
    Chin J Integr Med; 2022 Mar; 28(3):208-214. PubMed ID: 34897593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial.
    Li N; Zhao W; Xing J; Liu J; Zhang G; Zhang Y; Li Y; Liu W; Shi F; Bai Y
    BMC Complement Altern Med; 2017 May; 17(1):264. PubMed ID: 28506228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled single-blind clinical trial on 84 outpatients with psoriasis vulgaris by auricular therapy combined with optimized Yinxieling Formula.
    Lu CJ; Xiang Y; Xie XL; Xuan ML; He ZH
    Chin J Integr Med; 2012 Mar; 18(3):186-91. PubMed ID: 22466942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Moxibustion on plaque psoriasis of blood stasis: a randomized controlled trial].
    Chen ZX; Li P; Zhang GZ; Li B; Hu J; Feng S; Li BH; Lv JJ; Guo XW; Zhao JX; Di TT; Feng F; Wang Y
    Zhongguo Zhen Jiu; 2021 Jul; 41(7):762-6. PubMed ID: 34259409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial.
    Wen ZH; Xuan ML; Yan YH; Li XY; Yao DN; Li G; Guo XF; Ou AH; Lu CJ
    Trials; 2014 Jul; 15():294. PubMed ID: 25052161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of governor vessel moxibustion (GVM) therapy with mild to moderate psoriasis: A randomized clinical trial.
    Sun D; Feng WY; Mou JK; Chen L; Zhao YD; Yan XN; Li WB
    Medicine (Baltimore); 2023 Oct; 102(43):e35726. PubMed ID: 37904430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PSORI-CM01 granules and Yinxieling tablets for patients with chronic plaque psoriasis: a pilot study for a randomized, double-blinded, double-dummy, multicentre trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Lu LM; Wu HM; He ZY; Deng H; Deng JW
    Ann Palliat Med; 2021 Feb; 10(2):2036-2047. PubMed ID: 33549019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Pang RK; Fan YS
    Zhongguo Zhen Jiu; 2021 Jun; 41(6):608-12. PubMed ID: 34085476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
    Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
    JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
    Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whether Fire-needle Therapy Benefits Plaque Psoriasis: A Multicenter, Randomized, and Controlled Trial.
    Pan HD; Qi XL; Wang L; He JY; Liu JL; Zhang YB; Tian Y; Duan XW; Yang HY; Bai YP
    Chin J Integr Med; 2019 Apr; 25(4):259-263. PubMed ID: 30810976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial.
    Chen H; Sun J; Yang H; Sun Q; Zhang J; Gu J; Wen H; Li M; Liu X; Yang H; Lou D
    J Dermatol; 2020 Jul; 47(7):728-734. PubMed ID: 32346959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.